By 2026, the European landscape for plant extracts is entering a much more structured phase. Between increased controls on online commerce, evolving scientific standards surrounding CBD and Cannabis sativa L., and strengthened road safety policies, both consumers and professionals must navigate a constantly changing environment. For adult buyers in France and across Europe, this means one simple thing: choosing the right products becomes even more crucial.
This evolution doesn't just concern major brands or laboratories. It also affects small imported packages, dietary supplements sold through online marketplaces, next-generation cannabinoids, herbal products marketed as "wellness," and even how authorities assess drug use while driving. Here's how the European Union is attempting to harmonize this complex landscape, balancing consumer protection, innovation, and public safety.
A market for plant extracts undergoing a major transformation
The European market for plant extracts has diversified considerably in recent years. According to EUDA, the offering now includes low-THC products, highly concentrated extracts, edible forms, and even some semi-synthetic cannabinoids sold online in several Member States. This diversity creates opportunities for consumers, but it also makes the legal classification of products much more complex.
In practice, the same plant extract can be presented as a food supplement, a wellness product, a technical oil, or, in some cases, fall under the pharmaceutical category, depending on its composition, purity, and associated claims. It is precisely this gray area that is prompting European authorities to strengthen their common interpretation of the regulations. For consumers, this underscores the importance of choosing transparent products that are laboratory-tested and comply with local regulations.
The case of CBD is emblematic. Highly sought after for its non-intoxicating properties, it nevertheless remains subject to specific regulations at the European level. At the same time, the rise of e-commerce has dramatically increased access to products from a wide variety of sources, with varying levels of quality. The result: a growing need for traceability, analysis, and reliable information at the point of purchase.
E-commerce in the crosshairs of European authorities
In 2026, the European Union launched a new phase of targeted controls on imports from online commerce. Customs and food safety authorities are focusing particularly on small parcels, low-value shipments, and non-compliant products intended for European consumers. This strategy aims to better filter products that previously escaped traditional monitoring channels.
Supplements made from plant extracts are clearly among the segments being observed. The European Commission is now more directly linking e-commerce, consumer safety, and botanical products by integrating these actions into the framework of the Digital Services Act. In other words, online platforms and sellers are increasingly expected to ensure compliance, provide product information, and combat illegal offerings.
For the plant-derived cannabinoid sector, this vigilance is even more pronounced. EUDA points out that products containing low levels of THC or CBD, as well as some semi-synthetic cannabinoids, are circulating through online shops in several countries. For adult buyers, the best course of action is therefore to verify the origin of the hemp, laboratory analyses, stated THC levels, and the clarity of the regulatory framework before ordering.
Small parcels, platforms and cross-border operations
The strengthening of controls is not merely a political announcement. In March 2026, EU tax and customs authorities confirmed the intensification of coordinated inspections of food supplements sold through large online platforms and shipped in small packages. This is crucial, as many botanical products circulate precisely in this discreet and rapid format.
Another strong signal: OLAF announced Operation SHIELD VI on February 25, 2026. Conducted in 14 Member States, this action targeted counterfeit medicines, doping substances, and unregulated food supplements. While not all plant extracts are affected to the same level of risk, this operation clearly illustrates the increase in cross-border controls on sensitive products sold online.
For reputable market players, these controls can also have a positive effect. They help to clean up the supply by eliminating mislabeled, under-dosed, over-dosed, or imported products that do not comply with European regulations. For consumers, it's a useful reminder: a very low price never compensates for a lack of compliance, a certificate of analysis, or accurate information about the product's composition.
CBD, novel food and the European scientific framework
The regulatory status of CBD as a novel food remains a key issue in 2026. EFSA has reaffirmed that CBD falls under the Novel Food Regulation when it meets the applicable legal requirements. This position is crucial for all ingestible products based onhemp or cannabis extracts that wish to be marketed within a clear food framework in the EU.
EFSA has also published a provisional safe intake level of 0.0275 mg/kg/day, providing an important scientific benchmark, even though the overall picture regarding CBD remains evolving. For consumers, this demonstrates that the issue is not solely commercial: it also concerns the assessment of the safety, dosage, and quality of extracts used in oils, capsules, or other oral forms.
In March 2026, the EFSA issued an opinion on a CO₂ extract of Cannabis sativa L. as a novel food. This confirms that the regulation of cannabis/CBD plant extracts continues to progress through both scientific and regulatory channels. In short, Europe is not closing the door to these products, but requires robust data, precise characterization, and a demonstrated level of safety.
When a plant extract becomes a medicine
The distinction between food supplements and medicines remains one of the most sensitive issues in the sector. In 2026, European litigation remained active, with a preliminary ruling requested by the Dutch Council of State on March 26, 2026, concerning products sold online as food supplements. This case demonstrates that a product's classification depends not only on its packaging, but also on its composition and claimed effects.
The EMA, for its part, maintains a specific framework for herbal medicinal products. Its guidelines on extracts, purification, and scientific dossiers are central to plant extracts used for therapeutic purposes. If a product is presented with a medical purpose, contains certain concentrations, or is part of a structured pharmaceutical development process, it may fall under the category of medicinal product.
The EMA also updated its work on derived products and herbal monographs in 2026. This confirms that a cannabis product may fall under either medicinal product regulations or other regulatory frameworks, depending on its intended use and characteristics. For reputable brands, this implies very controlled communication; for consumers, it means clearly distinguishing between wellness products, supplements, and products used under controlled therapeutic conditions.
Clinical trials: the central role of the CTIS
When a plant extract is studied for therapeutic purposes, the regulatory environment changes. In the European Union, the reference system is now the Clinical Trials Information System, or CTIS. All clinical trials underway after January 30, 2025, must comply with Regulation (EU) 536/2014 via this platform, which harmonizes procedures and ensures transparency in trials.
This framework is particularly important for extracts made from cannabis or complex plants, as it mandates rigorous documentation of the quality of the tested product, its manufacturing process, standardization, and available safety data. This is far from a simple online sale: it is a scientific process designed to evaluate a therapeutic effect under controlled conditions.
For the general public, the existence of the CTIS helps to better understand the difference between potential benefit, user experience, and clinical evidence. A plant extract can be popular, promising, or appreciated in a wellness routine without necessarily having therapeutic validation. Conversely, well-conducted trials allow knowledge to advance credibly and clarify uses that are truly supported by data.
Roadside checks: another dimension of the debate
The issue of cannabis-derived plant extracts doesn't end with labeling or importation. It also affects driving. EUDA reminds us that driving under the influence of cannabis is illegal in all European countries. However, national approaches vary: some states use legal thresholds, others base their decisions on the mere presence of substances, and still others prioritize rules related to fitness to drive.
This heterogeneity creates a real challenge in understanding for adult consumers, particularly when they travel or order products in another European country. The thresholds, control methods, and legal consequences are not perfectly uniform. EUDA also specifies that some states are reviewing their THC limits for driving, as scientific data on impairment evolves.
Germany is often cited as a case study, with a legal limit of 3.5 micrograms per liter of blood serum for THC, presented by EUDA as corresponding to a risk of impairment comparable to a blood alcohol level of 0.2 g/L. This type of development shows that Europe is gradually seeking a better balance between road safety, clarity of regulations, and scientific reality. However, the practical message remains very simple: exercise extreme caution and never drive if in doubt.
What this changes for consumers and responsible sellers
The European framework for plant extracts is currently caught between three simultaneous dynamics: increased monitoring of e-commerce, scientific clarification of therapeutic uses, and modernization of roadside checks related to cannabis and cannabinoids. For consumers, this should not be seen solely as a constraint. It is also a way to improve the overall quality of the products available online.
In this context, responsible sellers have every reason to prioritize transparency: recent laboratory analyses, legal compliance, detailed product descriptions, clearly indicated origin, understandable composition, and the absence of dubious claims. This is precisely what distinguishes a reliable shop from an opportunistic offering. For enthusiasts of CBD, resins, oils, or newer cannabinoids, this transparency becomes a major purchasing criterion.
For buyers, a few key steps make all the difference: checking certificates, understanding the product's status, being wary of unregulated therapeutic claims, and remaining attentive to the regulations of their country, especially when traveling. The European market continues to evolve rapidly, but one trend is clear: legal, tested, and clearly presented products are gradually gaining ground in a more mature environment.
The year 2026 therefore marks a significant milestone for theEuropean regulation of plant extracts. The EU is tightening controls on online sales, refining the regulatory treatment of CBD and cannabis extracts, and more closely monitoring road safety issues related to cannabinoids. This convergence between customs, health authorities, digital regulators, and scientific agencies is creating a more coherent framework than before.
For adult consumers in France and Europe, the right course remains clear: prioritize products that are controlled, well-documented, and offered by reputable companies. In a rapidly evolving market, the best experience is not just a matter of price or novelty, but also of trust, compliance, and information. And in this area, plant extracts have every chance of establishing a lasting presence.
